论文部分内容阅读
目的观察国产胸腺肽α1(基泰)治疗恶性肿瘤的疗效。方法将150例不同类型恶性肿瘤患者随机分为3组,基泰+化疗(A)组,日达仙+化疗(B)组和单用化疗(C)组,在相同化疗条件下进行疗效对比。结果基泰在提高CD4+/CD8+和NK细胞比值,降低化疗毒副反应,提高生活质量以及缓解晚期非小细胞肺癌(NSCLC)病情等方面疗效都优于单用化疗对照(C)组(P<0.05)。但基泰组与日达仙组之间的疗效差异无显著性(P>0.05)。结论基泰联合化疗药物治疗恶性肿瘤是安全、有效和可行的,值得进一步推广应用。
Objective To observe the efficacy of domestic thymosin α1 (Ketai) in the treatment of malignant tumors. Methods A total of 150 patients with different types of malignant tumor were randomly divided into three groups: the combination of Keitai + Chemotherapy (A) group, Zadaxin + Chemotherapy (B) group and Chemotherapy alone group (C) . Results Ki-Tech was better than single-chemotherapy control group (C) in improving the ratio of CD4 + / CD8 + and NK cells, reducing the side effects of chemotherapy, improving the quality of life and relieving the condition of advanced non-small cell lung cancer 0.05). However, there was no significant difference between the two groups (P> 0.05). Conclusions The treatment of malignant tumor by combination of chemotherapy and radix is safe, effective and feasible, and it is worth further promotion and application.